NextCure announces acceptance of IND application for LNCB74

CAR-T Digest - August 2020

10 Dec 2024: NextCure announces acceptance of IND application for LNCB74

NextCure announced that the FDA accepted its Investigational New Drug (IND) application for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) designed to treat multiple cancers
The IND application is a significant milestone for NextCure, as it allows the company to proceed with the Phase 1 clinical trial for LNCB74
LNCB74’s preclinical data highlights its differentiation from other B7-H4-targeting ADCs, and NextCure believes it has the potential to transform cancer treatment
The IND submission includes comprehensive data on LNCB74, including its composition, pharmacology, toxicology, preclinical study results, trial protocols, and manufacturing details
LNCB74 is being developed in collaboration with LigaChem Biosciences, Inc. under a co-development agreement